Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs

Increasing the efficacy of targeted cancer therapies requires the identification of robust biomarkers suitable for patient stratification. This study focused on the identification of molecular mechanisms causing resistance against the anti-ERBB2-directed therapeutic antibodies trastuzumab and pertuz...

Descripción completa

Detalles Bibliográficos
Autores principales: Henjes, F, Bender, C, von der Heyde, S, Braun, L, Mannsperger, H A, Schmidt, C, Wiemann, S, Hasmann, M, Aulmann, S, Beissbarth, T, Korf, U
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412653/
https://www.ncbi.nlm.nih.gov/pubmed/23552733
http://dx.doi.org/10.1038/oncsis.2012.16

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412653/
https://www.ncbi.nlm.nih.gov/pubmed/23552733
http://dx.doi.org/10.1038/oncsis.2012.16

Ejemplares similares